PuSH - Publikationsserver des Helmholtz Zentrums München

Ordelheide, A.-M. ; Hrabě de Angelis, M. ; Häring, H.-U. ; Staiger, H.

Pharmacogenetics of oral antidiabetic therapy.

Pharmacogenomics 19, 577-587 (2018)
Postprint DOI PMC
Open Access Green
Type 2 diabetes prevalence is still on the rise worldwide. Antidiabetic drugs are widely prescribed to patients with Type 2 diabetes. Most patients start with metformin which is mostly well tolerated. However, a high percentage of patients fail to achieve glycemic control. The effectiveness of metformin as well as most other antidiabetic drugs depends among other factors on interindividual genetic differences that are up to now ignored in the treatment of Type 2 diabetes. Interestingly, many genes influencing the effectiveness of antidiabetic drugs are Type 2 diabetes risk genes making matters worse. Here, we shed light on these interindividual genetic differences.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Interindividual Differences ; Oad ; Oral Antidiabetic Drugs ; T2d ; Type 2 Diabetes; Planarian Schmidtea-mediterranea; Stem-cells; Rna-seq; Gene-expression; Regeneration; Pluripotency; Trajectories; Organism; Tissues; System
ISSN (print) / ISBN 1462-2416
e-ISSN 1744-8042
Zeitschrift Pharmacogenomics
Quellenangaben Band: 19, Heft: 6, Seiten: 577-587 Artikelnummer: , Supplement: ,
Verlag Future Medicine
Verlagsort 1200 New York Ave, Nw, Washington, Dc 20005 Usa
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes Research and Metabolic Diseases (IDM)
Institute of Experimental Genetics (IEG)